Lilly Archives - Vista Partners LLC | HomeVista Partners LLC

Vaccine Valuations: Lilly’s 4 Billion Dollar Bet & GeoVax’s Focused Grind – ( $GOVX $LLY )

by John F. Heerdink, Jr. May 26, 2026 165Views 0Likes

Eli Lilly’s (LLY) latest vaccine shopping spree and GeoVax Labs’s (GOVX) sharpened strategic focus together seemingly sketch a quietly bullish subplot in an otherwise noisy biotech market, giving investors a fresh angle on infectious disease and immuno-oncology risk-on exposure. Big Pharma…

From Waistlines to Warheads: How GLP‑1 Cash Is Quietly Fueling the Radiopharma Revolution -( $AZN $BMY $LLY )

by John F. Heerdink, Jr. April 20, 2026 248Views 0Likes

Eli Lilly is turning its GLP-1 windfall into a broader oncology and radiopharma push, just as a new generation of targeted alpha therapies steps onto center stage with companies like NAYA Therapeutics — and investors are starting to notice that “weight loss”…

From Shopping Carts to Smart Carts: Walmart’s Digital Health Push Meets Lilly’s GLP‑1 Boom – ( $AMGN $LLY $MODD $NVO $PFE $WMT )

by John F. Heerdink, Jr. April 20, 2026 172Views 0Likes

Walmart’s (WMT) latest move into digital health reads less like a retail side-hustle and more like an opening bell in the next leg of the GLP‑1 trade, with syringes, smartphones, and stock tickers all lining up on aisle 7. As weight‑loss drugs…

Tag: Lilly

Vaccine Valuations: Lilly’s 4 Billion Dollar Bet & GeoVax’s Focused Grind – ( $GOVX $LLY )

From Waistlines to Warheads: How GLP‑1 Cash Is Quietly Fueling the Radiopharma Revolution -( $AZN $BMY $LLY )

From Shopping Carts to Smart Carts: Walmart’s Digital Health Push Meets Lilly’s GLP‑1 Boom – ( $AMGN $LLY $MODD $NVO $PFE $WMT )

Your Guide To Staying Informed In The Markets